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Abstract
Analogs of the cyclic nucleotides cAMP and cGMP have been extensively used to mimic or modulate cellular events
mediated by protein kinase A (PKA), Exchange protein directly activated by cAMP (Epac), or protein kinase G (PKG). We
report here that some of the most commonly used cyclic nucleotide analogs inhibit transmembrane transport mediated by
the liver specific organic anion transporter peptides OATP1B1 and OATP1B3, unrelated to actions on Epac, PKA or PKG.
Several cAMP analogs, particularly with 8-pCPT-substitution, inhibited nodularin (Nod) induced primary rat hepatocyte
apoptosis. Inhibition was not mediated by PKA or Epac, since increased endogenous cAMP, and some strong PKA- or Epac-
activating analogs failed to protect cells against Nod induced apoptosis. The cAMP analogs inhibiting Nod induced
hepatocyte apoptosis also reduced accumulation of radiolabeled Nod or cholic acid in primary rat hepatocytes. They also
inhibited Nod induced apoptosis in HEK293 cells with enforced expression of OATP1B1 or 1B3, responsible for Nod
transport into cells. Similar results were found with adenosine analogs, disconnecting the inhibitory effect of certain cAMP
analogs from PKA or Epac. The most potent inhibitors were 8-pCPT-6-Phe-cAMP and 8-pCPT-29-O-Me-cAMP, whereas
analogs like 6-MB-cAMP or 8-Br-cAMP did not inhibit Nod uptake. This suggests that the addition of aromatic ring-
containing substituents like the chloro-phenyl-thio group to the purines of cyclic nucleotides increases their ability to inhibit
the OATP-mediated transport. Taken together, our data show that aromatic ring substituents can add unwanted effects to
cyclic nucleotides, and that such nucleotide analogs must be used with care, particularly when working with cells
expressing OATP1B1/1B3, like hepatocytes, or intact animals where hepatic metabolism can be an issue, as well as certain
cancer cells. On the other hand, cAMP analogs with substituents like bromo, monobutyryl were non-inhibitory, and could be
considered an alternative when working with cells expressing OATP1 family members.
Citation: Herfindal L, Krakstad C, Myhren L, Hagland H, Kopperud R, et al. (2014) Introduction of Aromatic Ring-Containing Substituents in Cyclic Nucleotides Is
Associated with Inhibition of Toxin Uptake by the Hepatocyte Transporters OATP 1B1 and 1B3. PLoS ONE 9(4): e94926. doi:10.1371/journal.pone.0094926
Editor: James Porter, University of North Dakota, United States of America
Received October 24, 2013; Accepted March 21, 2014; Published April 16, 2014
Copyright:  2014 Herfindal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported financially by the Norwegian Research Council [Projects 157338/187413] and the Norwegian Western Regional Health
authorities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflict: Dr. Frank Schwede is employed by the BIOLOG Life Science
Institute that sells the cyclic nucleotide analogs that were used in this study. All other authors have declared that no competing interests exist. This does not alter
the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: lars.herfindal@biomed.uib.no
¤ Current address: Department of Clinical Science, University of Bergen, Bergen, Norway
Introduction
Analogs of cAMP with increased phosphodiesterase resistance,
enhanced lipophilicity or specificity towards either of the cAMP-
binding proteins cAMP-dependent protein kinase (PKA) and
exchange protein directly activated by cAMP (Epac) have been
extensively used to study the action of these proteins both in
enzyme assays and in intact cells [1,2,3]. These analogs are
considered selective to the cAMP-binding proteins, with few side
effects, even from metabolites. One of the most used modifications
of cAMP is the introduction of a thiophenyl-substituent at the 8-
postion of the purine ring of cAMP. The corresponding analog 8-
pCPT-cAMP is, when added extracellularly, a potent stimulator of
cellular cAMP actions in intact cells, whether mediated by cAMP-
dependent protein kinases, or the Epac class of cAMP receptors.
However, recent studies have shown that metabolites of 8-pCPT-
modified cAMP-analogs or the analogs themselves can affect
signaling pathways or systems not regulated by cAMP-binding
proteins, such as cortisol synthesis [4,5], or binding of ligands to
purinergic adenosine receptors on platelets [6,7]. It is important to
unveil such unspecific effects to ensure proper interpretation of
cellular effects based on the use of nucleotide analogs.
The protein phosphatase (PP) inhibitors microcystin (MC) and
nodularin (Nod) induce liver and intestinal failure and are
considered a health hazard to humans if consumed in drinking
water [8]. Uptake of MC and Nod is through liver specific organic
anion-transporting polypeptides (OATP) [9,10] and cause intra-
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cellular inhibition of protein phosphatase 1 (PP1) and PP2,
generation of reactive oxygen species (ROS), and ultimately leads
to apoptosis [11,12,13]. We have previously reported that Nod
induced apoptosis is dependent on Ca2+/Calmodulin dependent
protein Kinase II (CaMKII) [14,15] and CaMKII inhibitors also
potently inhibits Nod induced death. We wanted to find a possible
role of cAMP signaling in Nod induced hepatocyte apoptosis. It is
already known that cAMP induces cell death alone in leukemia
cells [16,17], and can modulate cell death induced by apoptosis
inducers like Fas, TNFa, or anti-cancer drugs [18,19]. However,
we found effects of cAMP analogs that could not be ascribed to
either activation or inhibition of PKA or Epac.
OATP1B1/1B3 are responsible for the hepatocellular uptake of
MC and Nod [9,20], and we have recently shown that inhibition
of MC or Nod induced apoptosis may occur by inhibition of toxin
uptake by OATP1B1 and 1B3 [20]. In that study, we also
demonstrated a direct relationship between [3H]-Nod uptake and
the cell’s ability to undergo apoptosis. It is thus possible to measure
OATP1B1 or 1B3 activity as a function of apoptosis induction
[20]. OATP1B1 and 1B3 belong to the OATP1 subfamily and are
predominantly expressed in the liver under normal conditions
[21,22], but can also be expressed in some solid cancers
[23,24,25]. These proteins are responsible for uptake of several
endogenous substances and drugs, and play a pivotal role in
clearance of drugs from the blood stream (for a review, see [26]).
Due to their substrate promiscuity [27], it is likely that OATP1B1/
1B3 also interact with other compounds used both in the clinic and
biomedical research [26]. If currently used cAMP analogs interfere
with transport by these proteins they can alter the transport of
other agents and themselves be subject to uptake inhibition by
drugs or metabolites competing for transport into hepatocytes and
also in cancer cells expressing these transporters.
MC and Nod are unable to penetrate biological membranes
even if charged moieties are neutralized [28], but induce rapid
apoptotic cell death if microinjected into non-hepatocyte cells [13].
Our findings show that modification of cyclic nucleotides can alter
their substrate specificity to act on completely unrelated proteins.
We report here that analogs of cAMP, cGMP or adenosine, with
aromatic ring substituents inhibited OATP1B1/1B3 mediated
transport without any correlation with their ability to modulate
PKA or Epac activity. Some of these analogs are among the most
commonly used to mimic Epac and/or PKA activation. It is also
likely that aromatic ring substituents on other cyclic nucleotide
analogs than those tested here can also affect transport mediated
by OATP1B1/1B3. We call for caution when using such analogs
and suggest using combinations of several analogs before
concluding on effects mediated by PKA, Epac, or other enzymes
modulated by cyclic nucleotides.
Materials and Methods
Ethics statement
The experiments including isolation of rat hepatocytes were
approved by the Norwegian Animal Research Authority and
conducted according to the European Convention for the
Protection of Vertebrates Used for Scientific Purposes.
Chemicals
The cyclic nucleotide analogs used in this study were: 8-(4-
Chlorophenylthio)adenosine-39, 59-cyclic monophosphate (8-
pCPT-cAMP), 8-(4-Chlorophenylthio)-29-O-methyladenosine-39,
59-cyclic monophosphate, acetoxymethyl ester (8-pCPT-29-O-
Me-cAMP-AM), 8-(4-Chlorophenylthio)adenosine- 29-deoxyade-
nosine-39, 59-cyclic monophosphate (8-pCPT-dcAMP), 8-(4-
Chlorophenylthio)-29-O-methyladenosine-39, 59-cyclic monophos-
phate (8-pCPT-29-O-Me-cAMP), 8-(4-Chlorophenylthio)-29-O-
methyladenosine-39, 59-cyclic monophosphorothioate, Sp- isomer
(Sp-8-pCPT-29-O-Me-cAMPS), 8-(4-Chlorophenylthio)-29-O-
methyladenosine-39, 59-cyclic monophosphorothioate, Rp-isomer
(Rp-8-pCPT-29-O-Me-cAMPS), 8-(4-Chlorophenylthio)-N6-phe-
nyladenosine-39, 59-cyclic monophosphate (8-pCPT-6-Phe-
cAMP), 8-(4-Chlorophenylthio)-N6-phenyladenosine-29-deoxyade-
nosine 39, 59-cyclic monophosphate (8-pCPT-6-Phe-dcAMP), 8-
Bromoadenosine-39, 59-cyclic monophosphate (8-Br-cAMP), 8-
Bromoadenosine-39, 59-cyclic monophosphorothioate, Rp-isomer
(Rp-8-Br-cAMPS), 8-Bromo-29-O-methyladenosine-39, 59-cyclic
monophosphate (8-Br-29-O-Me-cAMP), N6-Monobutyryladeno-
sine-39, 59-cyclic monophosphate (6-MB-cAMP), 8-(4-Chlorophe-
nylthio)guanosine-39, 59-cyclic monophosphate (8-pCPT-cGMP),
8-Bromoguanosine-39, 59-cyclic monophosphate (8-Br-cGMP), 8-
(4-Chlorophenylthio)adenosine (8-pCPT-Ado), 8-(4-Chlorophe-
nylthio)-29-O-methyladenosine (8-pCPT-29-O-Me-Ado), N6, 29-
O-Dibutyryladenosine-39, 59-cyclic monophosphate (DB-cAMP,
Bucladesine). All cAMP, cGMP and Ado analogs were from
Biolog LSI (Bremen, Germany). Nod was isolated from the
cyanobacterium Nodularia spumigena strain AV1 as described [28],
and labeled with [3H] by reduction with sodium boro[3H]hydride
(Amersham Biosciences, Little Chalfont, U.K.) by the method
given in [29]. [14C]-Glycocholic acid was from Amersham
Biosciences, and Rifamycin SV, adenosine, cAMP and cGMP
were from Sigma-Aldrich (St. Louis, MO, USA).
Cell handling and experimental conditions
Primary rat hepatocytes were isolated from male Wistar rats by
in vitro collagenase perfusion [30,31]. Isolated hepatocytes were
suspended (1.26106 cells/ml) in pregassed (95% O2/5% CO2)
low-phosphate incubation buffer (10 mM Hepes, pH 7.4, with
120 mM NaCl, 5.3 mM KCl, 0.01 mM KH2PO4, 1.2 mM
MgSO4, 1.0 mM CaCl2, 5 mM lactate, 5 mM pyruvate, and
0.5% bovine serum albumin) and allowed to condition in an
incubator (37 uC, 5% CO2, humidified atmosphere) for 20 min
prior to, and during the experiments. The cells were seeded in 48-
well tissue culture dishes, and analogs or vehicle added with or
without Nodularin (Nod). For microinjection, cells were seeded in
gridded petri dishes. Insulin (0.2 nM) and dexamethasone (5 nM)
was added after two hours of culture to maintain the metabolic
competence of the cultured hepatocytes, and EGF (9 nM)
20 hours after seeding to stimulate growth. Cells received
cytoplasmic injections of PKA subunit (RID199) dissolved in
93 mM K-PO4/14 m mM Na-PO4 buffer (pH 7.2) containing
3 mM MgSO4, 1 mM gluthatione and 0.3 mM ATP.
Human embryonic kidney cells (HEK293T, ATTC #: CRL-
11268) were cultured in Dulbecco’s modified eagle medium
(DMEM) supplemented with 10% fetal bovine serum (both from
Invitrogen, Carlsbad, CA) and antibiotics (50 U/mL of penicillin
and 0.05 mg/mL streptomycin). Enforced expression of green
fluorescent protein (GFP) alone, or with OATP1B3 or OATP1B1
was obtained by calcium phosphate transfection of cells for 6 h.
Vectors for OATP1B1 [22], and 1B3 [21] were a gift from
Dietrich Keppler, German Cancer Research Center, Division of
Tumour Biochemistry, Heidelberg, Germany.
Measurements of intracellular cAMP levels in un-transfected
HEK293T cells were conducted as previously described [32].
Estimation of sodium fluorescein accumulation in OATP1B1/1B3
transfected cells was as described by [33], except that the cells were
seeded in 24-well tissue culture plates at a density of 200 000 cells/
well. Inhibitors were added 10 min prior to addition of sodium
fluorescein, and the cells were then co-incubated with inhibitor
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and substrate for three min before removal of medium and
washing.
Immunofluorescence staining and confocal microscopy
HEK293T cells with enforced expression of OATP1B3 cultured
on cover slips were fixed in 2% paraformaldehyde and
permeabilized using 0.1% Triton X-100 in PBS. The samples
were blocked in PBS containing 1 mg/ml BSA and 0.05% Triton
X-100. Visualization of OATP1B3 was by immune-staining using
rabbit anti-OATP-8, (Santa Cruz Biotechnologies, Santa Cruz,
CA) and a FITC-conjugated goat anti-rabbit secondary antibody.
Actin was visualized by fluorescein-conjugated phalloidin (F432,
Molecular Probes, Leiden, Netherlands), and DNA by Hoechst
33342, and images were acquired by a Zeiss LSM 510 META
confocal laser microscope fitted with a 40x/1.3 NA Plan-Neofluor
oil-immersion objective (Zeiss, Oberkochen, Germany).
Determination of hepatocyte uptake of radiolabeled
nodularin and clycocholic acid
Freshly prepared primary rat hepatocytes in suspension (800
000 cells/ml) were incubated in buffer with cyclic nucleotide
analogs, sulfobromophthalein (BSP) or vehicle for 15 min.
Radiolabeled [3H]-Nod was added and the cells were incubated
for another 5 min before rapid separation from the medium by
centrifugation through a layer of a mixture of dibutyl and dinonyl
phthalate [20,34]. The cell pellet was lysed in 1 ml of 2% sodium
dodecyl sulfate (SDS) for 1 h and the radioactivity determined by
scintillation counting (TriCarb 3100TR, Perkin Elmer, Waltham,
MA). The accumulation of [14C]-glycocholic acid was determined
similarly, except that the cells were separated from the medium by
gentle filtration (0.45 mm HA filters, Millipore, Billerica, MA). The
filters, containing the cells, were washed twice with 2 ml of
incubation medium (37 uC), and processed for scintillation
counting (TriCarb 3100TR) using Emulsifier-SafeTM (Perkin
Elmer, Waltham MA) to dissolve the cells. We found that
50 mM of BSP was sufficient to obtain complete inhibition of Nod
or glycocholic acid uptake.
Estimation of IC50 values of cyclic nucleotide analogs
Experiments were conducted 48-well tissue culture plates (35
000 cells/well). Every cyclic nucleotide analog was tested for its
ability to inhibit Nod-induced apoptosis in OATP1B1- or 1B3-
transfected HEK293 cells with a dose curve from 1 to 300 mM.
Analogs were added to the transfected HEK293T cells 15 min
prior to addition of Nod, and the cells were thereafter incubated
for another 90 min with both analog and Nod. For some analogs,
medium without serum was used to avoid enzymatic degradation
of the analogs. This did not affect the cell’s response to Nod.
Apoptosis was assessed by microscopic evaluation of surface
budding of GFP positive cells [20] using a Zeiss Axiovert 35 M
inverted fluorescence microscope (Carl Zeiss MicroImaging
GMbH, Go¨ttingen, Germany). In brief, cells responding to Nod
detached, had polarized blebbing and condensed actin. For
estimation of cell death, only the population of GFP-positive cells
was used. The data was used to estimate IC50 values by four-
parameter curve fitting using SigmaPlot software (Systat Software
Inc. San Jose, CA):
y~minz
max{min
1z x
IC50
 Hillslope ð1Þ
IC50~Ki 1z
S
Km
 
ð2Þ
Nonlinear regression to estimate IC50 was performed using Eq.
1, where y is percent apoptotic cells observed, min is percent
apoptosis in non-treated cells, max is the percent apoptosis in
absence of inhibitor, at the given concentration of Nod, and x is
concentration of inhibitor. At certain conditions the IC50 value is
related to the competitive inhibitory constant (Ki) of the
transporter for the inhibitor x (Eq. 2), where S is the extracellular
concentration of toxin accessible for the transporter with half
maximal transport rate at S=Km.
We have previously described how competitive inhibitors of the
nodularin transporters can be robustly assessed by a sensitive
apoptosis assay [20]. A sigmoid function (i.e. a Hill equation) is
used as the apoptosis process show a cooperative response curve,
where the steepness depends on the cell type used and the time of
measurements. In the case where only transport of the toxin
determine the time of death of cells, the IC50 value of Eq. 1 would
relate to the inhibitory constant (Ki), however with different values
depending on the level of toxin present (S) during the assay and of
the affinity of the toxin for the transporter (Km, Eq. 2). These
calculations are presented in Table S1.
The data for uptake of fluorescein into HEK293T cells
transfected with OATP1B1 or OATP1B3 in the absence or
presence of inhibitor were fitted in SigmaPlot, using Michaelis
Menten kinetics with competitive inhibition. Vmax and Km values
obtained in absence of inhibitor were used to fit the Ki value for
uptake in the presence of inhibitor.
Results
cAMP analogs inhibit nodularin induced hepatocyte
apoptosis independently of PKA or Epac activation
We first tested if cAMP analogs directed towards PKA, Epac or
both enzymes could modulate nodularin (Nod) induced hepatocyte
apoptosis. Nod alone induced apoptotic morphology (Fig. 1A and
C), and activation of PKA by 6-MB-cAMP gave no change in
apoptosis induction (Fig. 1A). However, both the Epac activator 8-
pCPT-29-O-Me-cAMP and the non-selective analog 8-pCPT-
cAMP inhibited completely apoptotic morphology in the primary
hepatocytes (Fig. 1A, D and E). This was in contrast to the finding
that elevation of intracellular cAMP by glucagon and IBMX [35] did
not alter the Nod effect (Fig. 1A). To further probe the role of PKA in
Nod-induced hepatocyte apoptosis, we added the PKA-inhibitor
Rp-8-Br-cAMPS to the hepatocytes prior to addition of Nod. Rp-8-
Br-cAMPS inhibited apoptotic morphology (Fig. 1F), and microin-
jection of the negative regulator of PKA, RI into hepatocytes was
also a potent inhibitor of Nod-induced hepatocyte apoptosis.
To study the effect of various analogs in detail, we treated
hepatocytes with different Epac and PKA selective cAMP analogs
before addition of Nod. Again, we found clear inhibition with
Epac activators such as 8-pCPT-cAMP, its 29-O-Me analog and
the thioate Sp-8-pCPT-29-O-Me-cAMPS. Intriguingly, the 29-
deoxy variant 8-pCPT-dcAMP, which hardly affects PKA or
Epac, also blocked Nod-induced apoptosis (Fig. 2A). We wanted to
explore whether the lack of inhibition by endogenous elevation of
cAMP by glucagon/IBMX (Fig. 1A and 2A) was due to activation
of PKA. The addition of these agents increases endogenous levels
of cAMP in hepatocytes [35] (see also Fig. S1 for the effect on
HEK293-cells), and activates PKA. We added a combination of
the PKA activator 6-MB-cAMP and the Epac activator 8-pCPT-
29-O-Me-cAMP. However, the combination of these analogs was
Nucleotide Analogs Inhibit OATP
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an equally potent inhibitor of Nod-induced hepatocyte apoptosis
as 8-pCPT-cAMP or 8-pCPT-29-O-Me-cAMP alone (Fig 2A).
Moreover, the membrane permeable, bioactivatable AM-ester
[36] 8-pCPT-29-O-Me-cAMP-AM did not inhibit Nod-induced
apoptosis (Fig. 2A), excluding intracellular effects of the analogues,
but rather indicating effects at the cell membrane.
We thus concluded that the analog’s ability to inhibit Nod-induced
apoptosis was not related to modulation of PKA and/or Epac.
The ability of cAMP analogs to inhibit apoptosis
coincides with inhibition of hepatocyte uptake of
nodularin or bile acid
Nod and MC are internalized into hepatocytes by liver-specific
broad substrate transporter proteins (OATP1B1 and 1B3 in
human, Oatp1b2 in rat) [37]. We added radiolabeled MC or Nod
to investigate if the inhibiting analogs decreased accumulation of
toxins inside the primary hepatocytes. The same analogs that
inhibited Nod-induced cell death (Fig. 1A and 2A) significantly
decreased accumulation of [3H]-Nod (Fig. 2B). It thus appears that
some cAMP analogs inhibit OATP1B1/1B3-mediated toxin
transport into hepatocytes. These transporters can, together with
others such as Na+-dependent taurocholate co-transporting
polypeptide (NTCP), OATP1A2 and 2B1, also transport bile
acids into hepatocytes [38], and we replaced [3H]-Nod with [14C]-
glycocholic acid (GCA) to investigate if cAMP-analogs could
inhibit a broad range of bile acid transporters. Sulphobromo-
phthalein (BSP) was used to achieve full inhibition [20]. In the first
set of experiments with [14C]-GCA, we were puzzled to find that
8-pCPT-cAMP did not inhibit accumulation, but caused a slight
Figure 1. The ability of cAMP-analogs to modulate Nod-induced apoptosis is not related to the cAMP activated proteins PKA or
Epac. A: Freshly isolated hepatocytes were incubated with the given analogues or vehicle for 15 min before addition of 150 nM nodularin. The cells
were incubated for another 60 min before fixation in 2% buffered formaldehyde, and apoptosis scored by microscopic evaluation of surface
morphology. The data are average of 3–5 experiments and SEM. B–E: Surface morphology of normal hepatocytes (B), hepatocytes treated with
150 nM Nod alone (C), hepatocytes treated with 150 nM Nod and 8-pCPT-cAMP (D) or 8-pCPT-29-O-Me-cAMP (E) 15 min before addition of Nod. Bar
represent 20 mm. F: Hepatocytes were treated as in A, but given the 300 mM of the PKA inhibitor Rp-8-Br-cAMPS. G: Primary hepatocytes were
cultured for three days before microinjection with vehicle, Rp-8-Br-cAMPS or the negatively dominant mutant PKA R-subunit RID199. One hour
thereafter, the cells were microinjected with Nod to reach a final concentration of 2 mM inside the cells, and percent apoptosis was scored. The data
represent the average of three to four experiment where 10-15 cells were microinjected, and SEM.
doi:10.1371/journal.pone.0094926.g001
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increase of [14C]-GCA inside the hepatocytes, similar to the PKA
activator 6-MB-cAMP (Fig. 2C). However, the inactive 29-deoxy
variant 8-pCPT-dcAMP inhibited uptake, and as with [3H]-Nod
(Fig. 2B), the Epac activator 8-pCPT-29-O-Me-cAMP and Sp-8-
pCPT-29-O-Me-cAMPS almost completely inhibited [14C]-GCA
accumulation (Fig. 2C). Again, we found no inhibitory effect of the
membrane permeable Epac-agonist 8-pCPT-29-O-Me-cAMP-AM
(Fig. 2C). Surprisingly, we found an inverse dose-dependence
relationship (Fig. S2) between PKA activation and [14C]-GCA
accumulation, with increasing doses of either 8-pCPT-cAMP or 6-
MB-cAMP leading to reduced accumulation. In fact 200 mM of 8-
pCPT-cAMP led to accumulation of 60% compared to control. A
similar trend was seen with 6-MB-cAMP where the accumulation
of [14C]-GCA decreased from about 1.7 with 50 mM of to 1.1 (rel.
to control) using 400 mM (Fig. S2). It thus appears that low
concentrations of PKA activators could enhance accumulation of
[14C]-GCA.
We conclude that there is a correlation between cAMP-analog’s
ability to inhibit Nod-induced hepatocyte apoptosis and to prevent
accumulation of substrates of OATPs and other bile acid
transporters.
Figure 2. The ability of cAMP analogs to inhibit hepatocyte apoptosis coincides with inhibition of Nod and bile acid uptake. A:
Freshly isolated hepatocytes were incubated with vehicle or cAMP analogs (50 mM) for 15 min before addition of 150 nM nodularin followed by co-
incubation for another 60 min. The cells were next fixed and apoptosis scored as described in Figure 1. B: Freshly isolated hepatocytes were
incubated with vehicle or cAMP analogs (50 mM) for 15 min before addition of [3H]-nodularin. The cells were incubated for another 5 min before
separation of cells from supernatant and determination of intracellular radioactivity as described in the Experimental section. C: Freshly incubated
hepatocytes were treated as in B, but added [14C]-glycocholic acid instead of nodularin. Cells were separated from supernatant by gentle filtration
and intracellular radioactivity determined. The concentration of cAMP analogs in B and C is 50 mM. The data are average from 3-5 experiments and
SEM.
doi:10.1371/journal.pone.0094926.g002
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Linking common structural moieties with ability to
inhibit OATP1B1 and 1B3
Having disconnected the analog’s PKA- and Epac-modulating
effects from their ability to inhibit Nod-induced apoptosis, we next
wanted to establish which structural moieties were responsible for
the inhibition. We transfected HEK293T cells with OATP1B1 or
1B3, and studied their ability to undergo Nod-induced apoptosis
with or without analogs present in the medium. The cells
expressed the channels at the surface (Fig. 3A and D), close to
the cortical actin (Fig. 3B and C). While cells transfected with
empty vector remained unaffected upon Nod treatment (Fig. 3E
and H), the cells transfected with either of the channels showed
typical signs of Nod-induced apoptosis like detachment from the
surface, polarized membrane blebbing, and relocalization and
condensation of actin to the area of bleb origin [15] (Fig. 3F, G, I
and J). The LC50 value of Nod was 50 nM for OATP1B1-
expressing cells, and 220 nM for OATP1B3-expressing cells after
90 min incubation (Fig. 3K). The apoptogenic effect of Nod in the
OATP1B1/1B3 transfected cells was abolished if the inhibitor
rifamycin SV [39] (Fig. 4A) or 8-pCPT-29-O-Me-cAMP (Fig. 4B)
was added 15 prior to addition of Nod, whereas 6-MB-cAMP had
no inhibitory effect (Fig. 4C). IBMX (250 mM) did not affect Nod-
induced apoptosis in the OATP1B1/1B3 transfected cells (data
not shown). We next tested whether 8-pCPT-29-O-Me-cAMP also
could inhibit the accumulation of the OATP1B1/1B3 substrate
sodium fluorescein [33] into transfected HEK293T cells. The Km
value for fluorescein uptake in our system was 4026140 mM for
OATP1B1 and 2856134 mM for OATP1B3 (6 s.e. of the
estimate). The regression analysis showed that 8-pCPT-29-O-Me-
cAMP inhibited sodium fluorescein accumulation in a competitive
manner with Ki value of 46621 mM for OATP1B1 and
75622 mM for OATP1B3 (R2 values for regressions, 0.79 and
0.91 respectively). We concluded that the nodularin based method
and fluorescein method both showed potent inhibition of
OATP1B1/1B3 substrates by 8-pCPT-29-O-Me-cAMP. Although
more complex and cumbersome, the Nod based method had the
advantage that the background apoptosis was negligible (less than
5% in non-transfected cells).
We next incubated OATP1B1- or 1B3-expressing HEK293T
cells with various concentrations of cAMP analogs and calculated
their IC50 value towards Nod-induced apoptosis (Figure 4 and
Table 1). The incubation time with analogs was 15 min, which is
sufficient to modulate activity of PKA in blood platelets [6] and
cardiomyocytes [40], or Epac in endothelial cells [41], to reveal a
role of these enzymes in Nod-mediated apoptosis in HEK293T
cells. We found that all cAMP analogs containing the 8-pCPT-
moiety were potent inhibitors of OATP1B1/1B3 mediated Nod
transport. These analogs were more potent inhibitors of
OATP1B3 than 1B1. Noteworthy, the addition of a 29-O-Me-
moiety significantly increased the ability to inhibit transport
through both channels, whereas the 29-deoxy variant 8-pCPT-
dcAMP, which hardly affects PKA or Epac, was only slightly less
potent than the PKA/Epac activator 8-pCPT-cAMP.
To explore whether the aromatic phenyl functionality could be
the pivotal factor for cAMP-analogs to inhibit OATP1B1/1B3, we
tested analogs with two such moieties. The analog 8-pCPT-6-Phe-
cAMP and its 29-deoxy variant were very potent inhibitors of both
channels, with IC50 values well below 10 mM. This also provided
even stronger evidence for lack of involvement of Epac activation,
since the 6-substitution eliminate any activitory effect against Epac
[1].
We next wanted to know if other commonly used substituents in
cAMP analogs affected their ability to inhibit OATP1B1/1B3.
Neither the 8-Br nor the 6-MB substitutions affected OATP1B1/
1B3 transport. The addition of 29-O-Me to 8-Br-cAMP did not
affect OATP1B1 activity, but slightly inhibited OATP1B3. In line
with this, addition of a 29-O-butyryl substituent to 6-MB cAMP, to
produce DB-cAMP, also led to weak inhibition of OATP1B3
activity, but not to OATP1B1 activity.
Finally, we tested if other nucleotide/nucleoside analogs could
inhibit the liver transporters. Again, we found that the chemical
introduction of an 8-pCPT substitution to either cGMP or
adenosine (Ado) rendered them able to inhibit OATP-mediated
Nod-transport, whereas for instance 8-Br-cGMP was inactive. We
Figure 3. HEK-293T cells expressing OATP1B1/1B3 undergo
apoptosis upon nodularin treatment. A-D: Confocal micrographs
of a HEK-293T cell with enforced expression of OATP1B3. Visualization
of OATP1B3 stained green (A), F-actin stained red (B), and composite
image (C) of OATP1B3 (green), F-actin (red) and nucleus (blue). D: 3D
composite micrograph showing cell membrane localization of
OATP1B3. E-J: Phase contrast and fluorescent micrographs of HEK-
293T cells co-transfected with GFP and empty vector (E, H), OATP1B1 (F,
I) or -1B3 (G, J) treated with nodularin. After nodularin exposure for 90
minutes, the OATP-expressing cells showed distinct polarized budding
(F, G) with hypercondensed actin (I, J), whereas cells treated with empty
vector remained unaffected (E, H). K: HEK-293T cells expressing
OATP1B1 or -1B3, were treated with various concentrations of Nod
for 90 min before assessment of apoptosis based on surface
morphology (E–G). Only GFP-positive cells were counted.
doi:10.1371/journal.pone.0094926.g003
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also noted that 8-pCPT-29-O-Me-Ado was far more potent than
8-pCPT-cAMP, in line with the results for the respective cAMP
analogs.
Taken together, the results in Table 1 indicate that the
substituents 8-pCPT, 6-Phe and 29-O-Me favor inhibitory
properties of cyclic nucleotide analogs towards OATP1B1/1B3
(Fig. 5B) whereas the AM-esterification, 8-Br- and 6-MB
substituents do not affect OATP1B1/1B3 activity (Fig. 5C). Native
cAMP, cGMP or Ado did not affect OATP1B1/1B3 mediated
transport of Nod into HEK293 cells (Table 1).
Discussion
Based on the results presented, we conclude that cAMP analogs
must be used with care when working with cells expressing bile
Figure 4. 8-pCPT-cAMP inhibits Nod-mediated apoptosis in OATP1B1- or 1B3 transfected HEK293T cells. HEK293T cells were
transfected with OATP1B1 or OATP1B3, and treated with the OATP1B1/1B3 inhibitor rifamycin SV, or the cAMP analogs 8-pCPT-cAMP or 6-MB-cAMP
for 15 min before addition of Nod (0.1 mM for OATP1B1 and 0.6 mM for OATP1B3). After another 90 min incubation, the cells were fixed, and
apoptosis assessed as described in the methods section. The results show cell death relative to that induced by Nod without cAMP analogs, and are
mean and s.e.m. of 3-5 experiments.
doi:10.1371/journal.pone.0094926.g004
Table 1. Ability of various nucleoside analogues to inhibit HEK293T-cell apoptosis induced by nodularin1.
OATP1B1 OATP1B3
Analog IC50 R2 IC50 R2
cAMP .300 – .300 –
pCPT-substituted cAMP analogs 8-pCPT-cAMP 130 0.98 49.6 0.98
8-pCPT-dcAMP 223 0.94 55.7 0.98
8-pCPT-29-O-Me-cAMP 46.4 0.98 12.6 0.96
Sp-8-pCPT-29-O-Me-cAMPS 19.9 0.95 8.7 0.96
Rp-8-pCPT-29-O-Me-cAMPS .300 – .300 –
8-pCPT-6-Phe-cAMP 6.2 0.98 3.0 –
8-pCPT-6-Phe-dcAMP 8.2 – 8.00 –
Br-substituted cAMP analogs 8-Br-cAMP .300 – .300 –
Rp-8-Br-cAMPS .300 – .300 –
8-Br-29-O-Me-cAMP .300 – .300 –
Butyryl-substituted cAMP analogs 6-MB-cAMP .300 – .300 –
DB-cAMP .300 – 119 0.64
cGMP analogs cGMP .300 – .300 –
8-pCPT-cGMP 259 0.98 88.8 0.98
8-Br-cGMP .300 – .300 –
Adenosine analogs Adenosine .300 – .300 –
8-pCPT-Ado .300 – 150 –
8-pCPT-29-O-Me-Ado 31.3 0.98 17.2 0.82
1: HEK293 cells transfected with either OATP1B1 or OATP1B3 were incubated with increasing doses of cAMP analogs for 15 min before addition of Nod (0.1 mM for
OATP1B1 and 0.6 mM for OATP1B3). After 90 min coincubation, the cells were fixed in 2% buffered formaldehyde, and percent apoptotic cells determined by
microscopic evaluation of surface membrane. The data was used to estimate IC50 values using a four parameter curve fitting (see Experimental section). The panels
show typical data for cAMP analogs inhibiting apoptosis (left) or analogs that do not interfere with apoptosis (right). All experiments were performed in triplicates or
more. The R2 for each regression analysis is shown.
doi:10.1371/journal.pone.0094926.t001
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acid carriers. We have identified three substituents that appear to
interfere with OATP1B1/1B3 transport (Fig. 5B); first the 8-para-
Chlorophenylthio (8-pCPT) group, which is common in several
analogs selective to Epac or PKA, or used to mimic elevated
cAMP levels. Secondly, the 29-O-Me substituent, which led to
increased potency of both 8-pCPT-cAMP and 8-pCPT-Ado
(Table 1). It also caused some inhibition of the Epac-selective
analog 8-Br-29-O-Me-cAMP against OATP1B3, but not 1B1
(Table 1). The third substituent affecting OATP-activity is the 6-
Phe group. The addition of this aromatic moiety to 8-pCPT-
cAMP led to a strongly increased potency of 10-fold for
OATP1B3, and 20-fold for OATP1B1. While these analogs are
reported to be potent PKA- or Epac1 agonists [1,42], the almost
inactive 29-deoxy-variant was equally active in our study (Table 1),
supporting that inhibition of Nod-induced apoptosis is PKA and
Epac independent.
Neither 8-Br, 6-MB, nor the AM-esterification affected Nod-
mediated transport (Figure 2, Table 1). It thus appears that the
addition of a bulky substituent at the N6-position is no prerequisite
for OATP-inhibition, while the presence of an aromatic ring
substituent is (Table 1 and Fig. 5B and C), pinpointing to potential
charge-transfer interactions with aromatic amino acids of the
channels. In line with this, we have found that the cyclic
pentapeptide Nostocyclopeptide-M1 containing three aromatic
tyrosine residues was a more potent inhibitor of OATP1B1/1B3
than either of the cAMP analogs tested here [20].
The interior of the transmembrane cylinders of OATP1B1 and
1B3 contain several aromatic amino acids [43] that can contribute to
p-p interactions [44,45], and positively charged Lys and Arg [46,47],
which can form strong cation-p interactions with aromatic parts of
the ligand [48] (see Fig. S3). Several studies have identified aromatic
or cationic amino acids as important in OATP1B1/1B3 mediated
transport [43,49]. This could explain why an increasing amount of
aromatic substituents on a substrate increased its ability to compete
with natural substrates of OATP1B1 and 1B3. Recent studies
showed that general inhibitors of OATP1B1 and 1B3 all had several
aromatic ring structures [39,50], as was the case with the most potent
inhibitors in the present study (Fig. 5B). However, the less studied
and structurally flexible extracellular loops of OATP1B1/1B3 could
also be regions for molecular interactions with cAMP analogs.
The analogs with high ability to inhibit OATP1B1/1B3
mediated transport are highly hydrophobic (logD, Fig. S4A and
B), which is in concordance with previous findings on OATP1B1/
1B3 inhibitors [50]. One could believe that their increased ability
to cross biological membranes [51] may favor intracellular effect,
but the even more permeable AM-ester of 8-pCPT-29-O-Me-
cAMP did not affect hepatocyte death or [3H]-Nod accumulation
(Fig. 2A and B), suggesting that the effect was not mediated
through the inside of the cells. It appears that the presence of
aromatic substituents is the major determining factor in our study
(Tab. 1 and Fig. 5). A surprising finding was the dramatic
difference between the Sp and Rp configuration of 8-pCPT-29O-
Me-cAMPS on the ability to inhibit Nod-induced apoptosis in
OATP1B1/1B3 transfected HEK293 cells (Table 1). A dihedral
scan did not reveal different preferences towards syn and anti
configuration between the Rp and Sp configuration of 8-pCPT-
29O-Me-cAMPS (Fig. S5), and the mechanisms behind this
discrepancy towards OATP-inhibition remains enigmatic.
Off-target effects of cyclic nucleotides have been reported in
other systems, such as inhibition of platelets [6,7,52]. The pCPT-
substituents at the 8-position have been identified as relevant for
the off-target effects on Equilibrative Nucleoside Transporter 1
and activation of A2A Adenosine Receptors in nucleated cells
[53]. In our system, we show that other substituents, such as 6-Phe
and 29-O-Me can additionally exhibit or enhance off-target effects
of cyclic nucleotides on OATP1B1 and 1B3.
The off-target inhibition of OATP1B1/1B3 by cyclic nucleotide
analogs is likely to be present in freshly isolated primary
hepatocytes or cell systems with enforced expression of these
channels. It has been shown that the expression of these channels
is significantly reduced in primary hepatocytes only 6 hours after
isolation [54]. However, several cancers [23,55,56,57] and cancer
cell lines [24,25] have increased expression of OATP1B3, and this
must be taken into consideration when working with cAMP and
cGMP analogs in non-primary cell systems. In such systems, also
analogs without aromatic ring substituents [1,2] and with little or
no effect on the OATP channels (Table 1) should be tested before
concluding that an effect is mediated via PKA or Epac.
Supporting Information
Figure S1 Elevation of intracellular cAMP in HEK293T
cells after stimulation by forskolin and IBMX. HEK293T
cells were added forskolin (50 mM) and IBMX (250 mM) and
processed for measurement of intracellular cAMP as described
Jensen et al. (Platelets 2011, 22, 8–19).
(TIF)
Figure 5. Chemical structures of A: cAMP, B: cAMP with substituents that favor inhibition of OATP1B1 and 1B3, and C: substituents
that do not interfere with OATP-activity. The structure in A shows the numbering of the atoms. The substituents in B and C are i: N6-phenyl, ii: 8-
para-chlorophenylthio, iii: 29-O-methyl, iv: acetoxymethyl ester, v: N6-monobutyryl, vi: 8-bromo.
doi:10.1371/journal.pone.0094926.g005
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Figure S2 Inverse relationship between dose and accu-
mulation of [14C]-glycocholic acid in hepatocytes. Rat
hepatocytes were incubated with the given concentrations of
cAMP analogs for 15 min before addition of [14C]-glycocholic
acid. After 15 min, the cells were separated from the medium and
radioactivity measured by liquid scintillation. Note that while low
concentrations (50 mM) of 8-pCPT-cAMP or 6-MB-cAMP cause
increased uptake of [14C]-glycocholic acid, higher concentrations
have less or no effect.
(TIF)
Figure S3 A computer-generated model of OATP1B1
shows several residues able to interact with aromatic
substituents on cAMP. Visualization of amino acids in the
transmembrane cylinder of OATP1B1, likely to interact with
aromatic parts of the cAMP analogs by either p-p interactions
(green) or cation-p interactions (red). The transmembrane model
of OATP1B1 was generated by the protein structure prediction
service Phyre2 (http://www.imperial.ac.uk/phyre/). Note that
this is a tentative model that lacks extra- and intracellular loops
that could be crucial in substrate recognition, and that only minor
alterations in 3D-structure can change amino acid orientation.
However, based on mutation studies (Li, N. et al. PloS ONE 2012,
7, e36647 and Gui, C. and Hagenbuch, B. Biochemistry 2008, 47,
9090-7.), several of the depicted amino acids are important for
substrate recognition and transport. Visualization of the protein
model was by Discovery Studio 3.1 (2011, accelrys software, www.
accelrys.com).
(TIF)
Figure S4 Ability to inhibit OATP1B1/1B3 mediated
uptake correlates with lipophilicity of the substituent on
the adenosine part, but not on the cyclic phosphate of
cAMP. The IC50 data (Table 1 in the original paper) was divided
by 100, and plotted against LogD. Log D was estimated with the
Calculator Plug-in in Marvin version 5.7 (2012) for Apple
(ChemAxon Ltd., www.chemaxon.com). The molecules were
drawn in 2D mode and converted to 3D structures with the fine
build clean 3D mode in Marvin. Standard ionic condition (0.1 M
Cl- and 0.1 M Na+/K+) was used for estimation of logD at pH
(7.4).
(TIF)
Figure S5 Dihedral scan of cAMP analogs reveal two
preferred conformations. Gaussian 09 was used to calculate
the energy profile as a function of dihedral angle connecting the
two cAMP ring systems. The dihedral angle was incremented by
10 degrees with geometry optimization at the HF/6-31G* level of
theory using the Gaussian 09 (Rev. b.01) software (Gaussian, Inc.,
Wallingford CT, 2009). The inserted structures show syn and anti
configuration.
(TIF)
Table S1 Based on the determined IC50 values (Table 1) we
have estimated the competitive inhibitor constant, Ki, of the tested
cyclic nucleotide analogs for OATP1B1 and OATP1B3. Unlike
IC50, this constant is not similarly dependent on experimental
conditions like toxin concentration and the Km value for Nod of
OATP1B1 and OATP1B3. See the Methods section and
(Herfindal et al. Mol Pharm. 2011, 8, 360-7) for details concerning
estimation of constants.
(DOC)
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